Choriocarcinoma Syndrome: A Rare and Serious Complication of Testicular Germ Cell Tumors.

chemotherapy choriocarcinoma germ cell tumors metastasis radiation

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Oct 2021
Historique:
accepted: 11 10 2021
entrez: 17 11 2021
pubmed: 18 11 2021
medline: 18 11 2021
Statut: epublish

Résumé

Choriocarcinoma syndrome is a rare complication of metastatic germ cell tumors. The hallmark of the condition is metastatic tumor hemorrhage. We describe the case of a 28-year-old man with metastatic testicular choriocarcinoma who presented with dyspnea on exertion and lightheadedness. Symptoms started two days after completing cycle one of fractionated bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Laboratory investigations showed severe anemia, with a hemoglobin of 5.4 mg/dL (normal: 13-17 mg/dL). His baseline hemoglobin was 15.1 mg/dL before chemotherapy initiation. Coagulation and hemolysis workup showed no significant evidence of disseminated intravascular coagulopathy or autoimmune hemolysis. Imaging showed a significant increase in the size of previous metastatic liver lesions with surrounding hypodensity representing hemorrhage. He was admitted to the intensive care unit and started on massive transfusion protocol. On the same day, he developed a maroon-colored stool. Urgent upper endoscopy showed blood in the entire stomach and the second part of the duodenum spurting out through the ampulla, which suggested bleeding from metastatic liver lesions into the biliary tree. No defined culprit vessel was identified on visceral angiography. Endoscopic and surgical interventions were unlikely to be successful in controlling the bleeding due to the diffuse nature. He underwent one dose of radiation therapy to the abdomen, which was successful in controlling the bleeding. He survived, and his chemotherapy was switched to etoposide, ifosfamide, and cisplatin (VIP) with no further episodes of bleeding.

Identifiants

pubmed: 34786260
doi: 10.7759/cureus.18681
pmc: PMC8580209
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e18681

Informations de copyright

Copyright © 2021, Abuhelwa et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

JRSM Short Rep. 2012 Jun;3(6):44
pubmed: 22768378
Case Rep Gastroenterol. 2016 May 19;10(1):193-8
pubmed: 27403124
Ann Intern Med. 1988 Oct 15;109(8):674-5
pubmed: 2458694
Am Fam Physician. 2018 Feb 15;97(4):261-268
pubmed: 29671528
N Engl J Med. 1997 Jul 24;337(4):242-53
pubmed: 9227931
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Clin Oncol. 2010 Dec;15(6):611-4
pubmed: 20544252
Acta Radiol Oncol. 1984;23(4):239-47
pubmed: 6093440
Int J Urol. 2008 Mar;15(3):263-4
pubmed: 18304226
Case Rep Oncol Med. 2019 Feb 24;2019:4092941
pubmed: 30918732
Open Access J Urol. 2011 Dec 30;4:1-8
pubmed: 24198649

Auteurs

Ziad Abuhelwa (Z)

Internal Medicine, The University of Toledo, Toledo, USA.

Waleed Kassabo (W)

Internal Medicine, The University of Toledo, Toledo, USA.

Ying Ning (Y)

Oncology, The University of Toledo, Toledo, USA.

Majdal Hjouj (M)

Internal Medicine, Al-Quds University, Jerusalem, PSE.

Abhijit Saste (A)

Oncology, ProMedica Toledo Hospital, Toledo, USA.

Classifications MeSH